Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 15/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030490 | 1.00 | CYP17A1 (0.54) | CYP17A1CYP3A4CA2CA1CYP2C9 | |
| SCHEMBL4029239 | 0.91 | CYP17A1 (0.66) | CYP17A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4025132 | 0.91 | CYP17A1 (0.66) | CYP17A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7536471 | 0.88 | CYP17A1 (0.52) | CYP17A1CYP3A4 | |
| SCHEMBL7537438 | 0.87 | CYP17A1 (0.65) | CYP17A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4025212 | 0.87 | CYP17A1 (0.65) | CYP17A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4025340 | 0.87 | CYP17A1 (0.65) | CYP17A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7537443 | 0.87 | CYP17A1 (0.65) | CYP17A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4028778 | 0.85 | CYP17A1 (0.54) | CYP17A1CYP3A4CA2CA1 | |
| SCHEMBL5752821 | 0.85 | CYP17A1 (0.62) | CYP17A1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222174-B1 | IMIDAZOL-4-YLMETHANOLS USED AS INHIBITORS OF STEROID C17-20 LYASE | TAKEDA PHARMACEUTICAL (JP) | 2009-05-27 | — | — | EP | disclosed |
| US-6649643-B1 | Antitumor, anticarcinogenic, and antimetastasis agents; benign prostatic hyperplasia, alopecia, endometriosis, uterine myoma, hirsutism, virilism, precocious puberty, mastopathy, and polycystic overay syndrome treatment | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-11-18 | — | — | US | disclosed |